Already on the market with a topical formulation of lotilaner for Demodex blepharitis, Xdemvy, Tarsus Pharmaceuticals Inc. is now pursuing a “pipeline-in-a-pill” strategy and developing the one-time veterinary antiparasitic agent in various formulations for Lyme disease, rosacea and meibomian gland dysfunction. On 22 February, the Irvine, CA-based company unveiled Phase IIa data showing strong tick-killing capability in human volunteers that it believes could position lotilaner as an on-demand prophylaxis for people at moderate-to-high risk for contracting Lyme disease.
Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease
Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.
More from Clinical Trials
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.